Avalo Therapeutics reported financial results for the quarter ended June 30, 2026, reporting a net loss of $36.4 million and cash reserves of $472.2 million sufficient to fund operations into 2029. The company announced plans to initiate a registrational Phase 3 program for abdakibart in hidradenitis suppurativa (HS) in the first half of 2027, following positive Phase 2 LOTUS results. Additionally, Avalo expects to submit an Investigational New Drug application for AVTX-010, a next-generation anti-IL-1β antibody, in the same timeframe. Ron Philip was appointed to the Board of Directors, and the company was added to the Russell 2000 and Russell 3000 indexes. Avalo Therapeutics is a clinical-stage biotechnology company developing therapeutics targeting the IL-1β pathway for immune-mediated inflammatory diseases.
